Look like the market was in a neutral mode this week; however, the overall short-term direction is still long.
Again, I made a few changes and it involved taking some profit from $TRXC and buying back some $DFFN. I got stopped out of my $TRXC trading shares when price took a turn downward on Tuesday. I then used some of the money to buy back $DFFN since its price shot up 15% in high volume on Tuesday with no news. Take a look at that long green bar with the ultra-high volume. With that kind of interest all of a sudden, I just opened myself to the possibilities that something is going to happen soon.
Take a look at the weekly chart below:I like the V look here or should I say “hockey stick” potential?
I also added to $AMRN this week. The news, “Amarin Announces Patent Litigation Settlement Agreement with Teva” could be used as an excuse for the price to start climbing up from here. With Teva out of the way, Amarin has a chance to transform itself into a biotech giant by 2029 if Reduce-it Trial is a success. Well, I guess this is a play that worth the risk to be in. I have a peculiar feeling that my taking Vascepa for the last five years is the very reason I’m still here typing out my thought on my blog post today.
Before taking the Vascepa, I had incidents in which I thought I was going to have a heart attack. Ever since I started taking Vascepa, I did not experience any incident which caused me to be concerned. It could be the placebo effect, but after five years, it got to be more than placebo. Hey, but this is just my personal anecdote so take it with a grain of salt.
$AEMD and $IBIO are the twins here as far as I’m concerned. I’m perfectly fine waiting for catalysts to appear out-of-the-blue. Bang! And history is made.
I was referring to the percentage increase in price.
$LRAD is still solid to me. I’ve no problem what-so-ever waiting for this one.
$TRXC is going to be a solid long-term hold once the adoption is becoming apparent. You can read my thought ->here.
Thanks to $TRXC gain this week, my port increased slightly despite negative drawdown from $IBIO and $AEMD.
Current positions (in alphabet order):
AEMD AMRN DFFN IBIO LRAD TRXC & cash (up 18.4% YTD)
My 2 cents
From my camera: